NCT05750355View on ClinicalTrials.gov

Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 10, 2022

Primary Completion Date

December 7, 2022

Study Completion Date

December 7, 2022

Conditions
Healthy Subjects
Interventions
DRUG

TPN171H 10 mg Group

6 subjects will receive TPN171H 10 mg, orally; 2 subjects will receive placebo, orally.

DRUG

TPN171H 30 mg Group

6 subjects will receive TPN171H 30 mg, orally; 2 subjects will receive placebo, orally.

DRUG

TPN171H 40 mg Group

6 subjects will receive TPN171H 40 mg, orally; 2 subjects will receive placebo, orally.

DRUG

TPN171H 50 mg Group

6 subjects will receive TPN171H 50 mg, orally; 2 subjects will receive placebo, orally.

Trial Locations (1)

201900

Huashan Hospital affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

Vigonvita Life Sciences

INDUSTRY